BlueCrest Capital Management’s United Therapeutics UTHR Stock Holding History

BlueCrest Capital Management’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-23,290	Closed	-$6.48M	–	284
2022 Q4	$6.48M	Buy	+23,290	New	+$5.88M	0.17%	65
2018 Q1	–	Sell	-3,084	Closed	-$456K	–	1638
2017 Q4	$456K	Sell	3,084 -9,183	-75%	-$1.17M	0.01%	543
2017 Q3	$1.44M	Buy	+12,267	New	+$1.57M	0.06%	304
2016 Q3	–	Sell	-12,351	Closed	-$1.31M	–	1005
2016 Q2	$1.31M	Buy	+12,351	New	+$1.38M	0.05%	317
2016 Q1	–	Sell	-9,855	Closed	-$1.54M	–	1120
2015 Q4	$1.54M	Buy	9,855 +7,144	+264%	+$1.04M	0.06%	307
2015 Q3	$356K	Buy	+2,711	New	+$435K	0.01%	668
2015 Q2	–	Sell	-14,437	Closed	-$2.49M	–	918
2015 Q1	$2.49M	Buy	+14,437	New	+$2.2M	0.13%	212

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

BlueCrest Capital Management's UTHR Position: Q1 2023 in Review

BlueCrest Capital Management sold out of United Therapeutics (UTHR) in Q1 2023, closing a stake of 23,290 shares — an estimated $6.48M sold.

BlueCrest Capital Management first reported a position in UTHR in Q1 2015 and held it in 7 quarters. The position peaked at $6.48M in Q4 2022. 505 funds tracked by Wall St. Rank hold UTHR as of Q1 2023.

BlueCrest Capital Management reported no remaining United Therapeutics position as of Q1 2023 after selling out during the quarter.
BlueCrest Capital Management sold 23,290 United Therapeutics shares in Q1 2023, an estimated $6.48M.
BlueCrest Capital Management first reported a position in United Therapeutics in Q1 2015 and held it in 7 quarters.
BlueCrest Capital Management's United Therapeutics position peaked at $6.48M in Q4 2022.
505 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2023.

Based on BlueCrest Capital Management's 13F filing for Q1 2023, filed 15 May 2023.